PMCA4b Inhibitors
PMCA4b inhibitors belong to a class of compounds that specifically target the plasma membrane calcium ATPase isoform 4b (PMCA4b). The PMCA family of proteins plays a crucial role in regulating intracellular calcium levels by actively transporting calcium ions out of the cell. Among the various isoforms, PMCA4b is particularly abundant in tissues with high calcium transport demands, such as the brain and the inner ear. As a critical component of cellular calcium homeostasis, PMCA4b is involved in the fine-tuning of numerous cellular processes, including neurotransmitter release, muscle contraction, and gene expression.
PMCA4b inhibitors are designed to modulate the activity of PMCA4b, thereby influencing calcium ion flux across the plasma membrane. By selectively inhibiting PMCA4b, these compounds can potentially impact downstream signaling pathways and cellular responses associated with calcium signaling. The development of PMCA4b inhibitors involves a detailed understanding of the enzyme's structure and function, enabling the design of molecules that can specifically interact with the active site or allosteric sites of PMCA4b. This specificity is crucial to avoid off-target effects and unwanted interference with other isoforms of the PMCA family.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Sesquiterpene lactone that disrupts calcium homeostasis by inhibiting the SARCO/ER Ca2+-ATPase (SERCA), which indirectly affects PMCA4b activity by altering intracellular calcium levels. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $45.00 $56.00 $183.00 | 142 | |
Transition state analog for phosphorylated proteins, including ATPases; acts as a general inhibitor of ATPase activity, including PMCA4b. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $184.00 $245.00 | 13 | |
Inorganic dye that blocks calcium channels, indirectly reducing the substrate availability for PMCA4b. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Calcium channel blocker that indirectly reduces PMCA4b activity by altering intracellular calcium concentrations. | ||||||
Lanthanum(III) chloride | 10099-58-8 | sc-257661 | 10 g | $88.00 | ||
Acts as a calcium channel blocker, which in turn can decrease the activity of PMCA4b by altering calcium gradients. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $27.00 $52.00 | 37 | |
Modulator that affects calcium channels and stores, thereby influencing PMCA4b activity indirectly by modifying calcium dynamics. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $173.00 $612.00 | 3 | |
Inhibitor of the SERCA pump, which may alter PMCA4b function indirectly by affecting calcium pools. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
L-type calcium channel blocker that indirectly modifies PMCA4b function by changing calcium fluxes. | ||||||
Sodium azide | 26628-22-8 | sc-208393 sc-208393B sc-208393C sc-208393D sc-208393A | 25 g 250 g 1 kg 2.5 kg 100 g | $42.00 $152.00 $385.00 $845.00 $88.00 | 8 | |
A general inhibitor of ATPases which might decrease the activity of PMCA4b by interference with ATP hydrolysis. | ||||||